Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer

Breast Cancer Research and Treatment

Volumn 117, Issue 2, 2009, Pages 289-295

  Thomas, R J ^a,b   Williams, M ^a   Glen, J ^c   Callam, M ^a  

^a BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

Anastrozole; Breast cancer; Cost effectiveness; Relapse

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 68949135797     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0289-6     Document Type: Article

References (26)

1. JF Forbes J Cuzick A Buzdar JS Tobias M Baum 2008 Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 months analysis of the ATAC trial Lancet Oncol 9 1 45 53 10.1016/S1470-2045(07)70385-6
2. RC Coombes E Hall L Gibson R Paridaens J Jassem 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 11 1081 1092 10.1056/NEJMoa040331
3. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 9484 455 462 10.1016/S0140-6736(05)67059-6
4. Breast International Group (BIG) 1-98 Collaborative Group B Thürlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med. 353 2747 2757
5. R Thomas J Green M Callam 2006 Adjuvant breast cancer drugs-blockbusters or bankrupters? Br J Canc Manag 2 3 5 9
6. R Mansel G Locker L Fallowfield A Benedict D Jones on Behalf of the ATAC Trialists' Group 2007 Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5 years completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Br J Cancer 97 152 161 10.1038/sj.bjc.6603804
7. M Baum ATAC Trialists' Group 2002 The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment Eur J Cancer 38 15 1984 1986 10.1016/S0959-8049(02)00154-5
8. F Boccardo A Rubagotti M Puntoni P Guglielmini 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial J Clin Oncol 23 22 5138 5147 10.1200/JCO.2005.04.120
9. H Mouridsen M Gershanovich Y Sun R Pérez-Carrión 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 10 2596 2606
10. E Remak L Brazil 2004 Cost of managing women presenting with stage IV breast cancer in the United Kingdom Br J Cancer 91 1 77 83 10.1038/sj.bjc. 6601890
11. C Skedgel D Rayson R Dewar K Potvin T Younis 2005 Economic evaluation of adjuvant hormonal options in post menopausal women with breast cancer: tamoxifen versus tamoxifen, then exemestane versus anastrozole J Clin Oncol 23 16s 538 Abstract number 6040
12. J Karnon GR Kerr W Jack NL Papo DA Cameron 2007 Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis Br J Cancer 97 4 479 485 10.1038/sj.bjc.6603887
13. Wolowacz S, Roskell N, Christie A, Kerr G, Cameron D (2005) The cost of hospital care for relapsed breast cancer in the UK based on a large patient-level resource utilisation dataset. Presented at the European Conference of the International Society for Pharmacoeconmics and Outcomes Research, Florence
14. Department of Health (7 March 2005) NHS Reference Costs 2004. Available via http://www.dh.gov.uk. Accessed 17 June 2008
15. British National Formulary (June 2007) Pharmaceutical Press, BMJ Publishing Group Ltd, London
16. Office for National Statistics Census 2001: Bedfordshire County. Available via: http://www.statistics.gov.uk/census2001/profiles/9.asp. Accessed 17 June 2008
17. West Anglia Cancer Network Available via http://www.wacn.org.uk. Accessed 17 June 2008
18. M Bontenbal GJ Creemers HJ Braun 2005 Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J Clin Oncol 23 28 7081 7088 10.1200/JCO.2005.06.236
19. M Martin A Villar A Sole-Calvo R Gonzalez B Massuti 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 6 833 842 10.1093/annonc/mdg260
20. JM Nabholtz A Buzdar M Pollak W Harwin 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 18 22 3758 3767
21. CL Vogel MA Cobleigh D Tripathy JC Gutheil 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 10.1200/JCO.20.3.719
22. DJ Slamon B Leyland-Jones S Shak H Fuchs 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101
23. National Institute for Health and Clinical Excellence (June 2008) Guide to the Methods of Technology Appraisal. Available via http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 16 July 2008
24. L Mauriac A Keshaviah M Debled H Mouridsen 2007 Predictors of early relapse in postmenopausal women with hormone receptor +ve breast cancer in the BIG-1-98 trial Ann Oncol 18 859 867 10.1093/annonc/mdm001
25. MJ Ellis A Coop B Singh L Mauriac 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for Erb B-1 and/or ErbB-2 positive, ER +ve primary breast cancer: evidence from a phase III randomised trial J Clin Oncol 19 18 3808 3816
26. PE Lønning J Geisler LE Krag B Erikstein 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 22 5126 5137 10.1200/JCO.2005.07.097